Yissum Technology Transfer Company of the Hebrew University of Jerusalemis raising $5 million to invest in agro biotechnology companies. Yissum has already closed a $5 million fund for investment in life sciences companies, and now plans to replicate the success.
Yissum Spin off RegeneCure announced today the successful results of a clinical study in pets using the company's regenerative membrane implant technology for the treatment of bone fractures. The study showed that the healing time was about 40 percent quicker than normally observed using current Standard of Care therapies. The product was also demonstrated to be safe in all of the study participants.
Drug developer Avraham Pharmaceuticals Ltd. has raised $5.7 million fromYissum Technology Transfer Company of the Hebrew University of Jerusalem.Technion Research and Development Foundation, Clal Biotechnology Industries Ltd. (TASE: CBI) and the Pontifax fund. Following the current investment round, Yissum and Integra Holdings, Yissum's biotech holdings company, will now hold 47% of the shares of Avraham Pharmaceuticals.
Israeli scientists introduce new varieties of the popular legume that retain high nutritional values and produce a better yield.
Hebrew University develops more nutritious chickpeas adapted to limited rainfall. Yissum, the university’s research and development company, has introduced new chickpea varieties that retain high nutritional values while showing improved synchronization between flowering and the rainy season, thereby increasing yield.
A serendipitous lab discovery led to a breakthrough vaccine for a fatal tick-borne disease. Now investors are sought to take it commercial
Results showing the effectiveness of the vaccine in dogs were recently published in the journal Vaccine
The company today reported positive results of the clinical trial of its drug for the treatment of necrotizing soft tissue infections.
When Ovadia Lev, Professor of Environmental Chemistry and Health at The Hebrew University of Jerusalem, and his research team developed a new coating technology a few years ago, they thought it was an interesting outcome of their research in hydrogen peroxide solutions. However, they weren't sure what to do with it until they met a team of researchers looking for a simple way to synthesize new lithium-ion battery anode materials, such as graphene-tin oxide composites.
Tiltan Pharma is one of the portfolio companies of Integra Holdings, a biopharmaceutical holding company founded by Yissum, the technology transfer company of the Hebrew University of Jerusalem.
The blind have long used other senses -- including touch -- to compensate for their visual impairment. But a new study finds that when images are conveyed as sound, even the congenitally blind can distinguish among objects and their brains respond as if they are seeing.
Integra Holdings closes U.S. $ 7.0 million private financing
One of six promising orphan Drugs currently under development in Israel, AB103 was granted Fast Track and Orphan Drug designations by the FDA.
Drug developer Atox Bio announced today that the US Food and Drug Administration (FDA) has granted fast track designation to AB103, its lead product, currently in development for the treatment of Necrotizing Soft Tissue Infections (NSTI).
Hebrew U. medical researchers find a tiny peptide encoded by the HIV virus could hold the key to making cancer therapies more successful.
Novel biocontrol agent is environmentally-friendly, non-toxic and effective for a large variety of plants
The novel method uses a peptide derived from HIV to increase the sensitivity of cancer cells to radiotherapy and chemotherapy
When Scientific American recently wrote about the progress in artificial intelligence, it profiled two IBM supercomputers: Deep Blue, which defeated the world champion Gary Kasparov in chess, and the Jeopardy-winning Watson. The other company it profiled is the little-known Mobileye, an Israeli firm whose strength lies in EyeQ, a chip with a dimension of only one square centimeter.
Montreal venture capitalist Matthew Price-Gallagher is bullish on Israel. The successful high-tech entrepreneur has been to the country about 20 times in the last two years, attracted to its refreshing “can-do” approach to business – and science.
Price-Gallagher, president and CEO of Water Cluster Scientific Inc., is collaborating with the Hebrew University of Jerusalem and its affiliated technology transfer company, Yissum, on research and development.